IL3RA and hematologic disorder: In a preclinical study, Gurunadh R. et al. [142] provided preclinical activity, safety, pharmacokinetic, and pharmacodynamic data supporting MGD006, a CD3 × CD123 bispecific DART capable of redirecting host T cells to kill CD123+ targets, as a potential therapeutic agent for the treatment of CD123+ hematological malignancies [142].